Investigation of the Inhibitory Effect of Simvastatin on the Metabolism of Lidocaine Both in vitro and in vivo

References

• SamarinMJ, MohrienKM, OliphantCS. Continuous intravenous antiarrhythmic agents in the intensive care unit: strategies for safe and effective use of amiodarone, lidocaine, and procainamide. Crit Care Nurs Q. 2015;38(4):329–344. doi:10.1097/CNQ.000000000000008226335213
   PubMedGoogle Scholar
• MaloneE, EnsinkJ, TurnerT, et al. Intravenous continuous infusion of lidocaine for treatment of equine ileus. Vet Surg. 2006;35(1):60–66. doi:10.1111/j.1532-950X.2005.00113.x16409411
   PubMed Web of Science ®Google Scholar
• SolísCND, IiiMK. Serum concentrations of lidocaine and its metabolites MEGX and GX during and after prolonged intravenous infusion of lidocaine in horses after colic surgery. J Equine Vet Sci. 2007;27(9):398–404. doi:10.1016/j.jevs.2007.07.007
   Web of Science ®Google Scholar
• RezendeML, WagnerAE, MamaKR, FerreiraTH, SteffeyEP. Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. Am J Vet Res. 2011;72(4):446–451. doi:10.2460/ajvr.72.4.44621453144
   PubMed Web of Science ®Google Scholar
• WagnerAE, MamaKR, SteffeyEP, FerreiraTH, RezendeML. Comparison of the cardiovascular effects of equipotent anesthetic doses of sevoflurane alone and sevoflurane plus an intravenous infusion of lidocaine in horses. Am J Vet Res. 2011;72(4):452–460. doi:10.2460/ajvr.72.4.45221453145
   PubMed Web of Science ®Google Scholar
• RademakerAW, KellenJ, TamYK, WyseDG. Character of adverse effects of prophylactic lidocaine in the coronary care unit. Clin Pharmacol Ther. 1986;40(1):71–80. doi:10.1038/clpt.1986.1413522031
   PubMed Web of Science ®Google Scholar
• HermanssonJ, GlaumannH, KarlénB, VonBC. Metabolism of lidocaine in human liver in vitro. Basic Clin Pharmacol Toxicol. 2010;47:49–52.
   Google Scholar
• ImaokaS, EnomotoK, OdaY, et al. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. J Pharmacol Exp Ther. 1990;255:1385–1391.2262908
   PubMed Web of Science ®Google Scholar
• BargetziMJ, AoyamaT, GonzalezFJ, MeyerUA. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther. 1989;46(5):521–527. doi:10.1038/clpt.1989.1802582709
   PubMed Web of Science ®Google Scholar
• BeckettAH, BoyesRN, AppletonPJ. The metabolism and excretion of lignocaine in man. J Pharm Pharmacol. 2011;18(S1):76S–81S. doi:10.1111/j.2042-7158.1966.tb07965.x
   Web of Science ®Google Scholar
• KeenaghanJB, BoyesRN. The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man. J Pharmacol Exp Ther. 1972;180:454–463.5010683
   PubMed Web of Science ®Google Scholar
• DirikoluL, LehnerAF, KarpiesiukW, et al. Identification of lidocaine and its metabolites in post-administration equine urine by ELISA and MS/MS1,2. J Vet Pharmacol Ther. 2010;23(4):215–222. doi:10.1046/j.1365-2885.2000.t01-1-00281.x
   Web of Science ®Google Scholar
• LambertzCK, JohnsonCJ, MontgomeryPG, MaxwellJR, FrySJ. Toxicity of topical lidocaine applied to the breasts to reduce discomfort during screening mammography. J Anaesthesiol Clin Pharmacol. 2012;28(2):200–204. doi:10.4103/0970-9185.9485922557743
   PubMedGoogle Scholar
• MaesA, WeilandL, SandersenC, GasthuysF, BackerPD, CroubelsS. Determination of lidocaine and its two N -desethylated metabolites in dog and horse plasma by high-performance liquid chromatography combined with electrospray ionization tandem mass spectrometry. J Chromatogr B. 2007;852(1–2):180–187. doi:10.1016/j.jchromb.2007.01.010
   PubMed Web of Science ®Google Scholar
• OniG, BrownS, BurrusC, et al. Effect of 4% topical lidocaine applied to the face on the serum levels of lidocaine and its metabolite, monoethylglycinexylidide | aesthetic surgery journal | oxford academic. Aesthetic Surg J. 2010;30(6):853–858. doi:10.1177/1090820X10386944
   PubMed Web of Science ®Google Scholar
• LibbyP, BuringJE, BadimonL, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56. doi:10.1038/s41572-019-0106-z31420554
   PubMed Web of Science ®Google Scholar
• HerringtonW, LaceyB, SherlikerP, ArmitageJ, LewingtonS. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res. 2016;118(4):535. doi:10.1161/CIRCRESAHA.115.30761126892956
   PubMed Web of Science ®Google Scholar
• GoldsteinJ, BrownM. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161(1):161–172. doi:10.1016/j.cell.2015.01.03625815993
   PubMed Web of Science ®Google Scholar
• NordestgaardBRG, JohnM, HumphriesC, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society. Eur Heart J. 2013;34(45):3478–3490. doi:10.1093/eurheartj/eht27323956253
   PubMed Web of Science ®Google Scholar
• PrueksaritanontT, GorhamLM, MaB, et al. In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos. 1997;25(10):1191–1199.9321523
   PubMed Web of Science ®Google Scholar
• YuanW, YiJ, YunX, WangM, DaiY, XiaY. Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. Life Sci. 2018;209:228–235. doi:10.1016/j.lfs.2018.08.01230096386
   PubMed Web of Science ®Google Scholar
• ZhouX-Y, Hu-X-X, Wang-C-C, et al. Enzymatic activities of CYP3A4 allelic variants on quinine 3-hydroxylation in vitro. Front Pharmacol. 2019;10. doi:10.3389/fphar.2019.00591
   Web of Science ®Google Scholar
• FangP, TangPF, XuRA, et al. Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro. Drug Des Devel Ther. 2017;11:3503–3510. doi:10.2147/DDDT.S152366
   PubMed Web of Science ®Google Scholar
• FDA. FDA Guidance for Industry Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling; 2006.
   Google Scholar
• HeJ, PingF, XiangZ, et al. Inhibitory effect of celecoxib on agomelatine metabolism in vitro and in vivo. Drug Des Devel Ther. 2018;12:513–519. doi:10.2147/DDDT.S160316
   PubMed Web of Science ®Google Scholar
• LiX, ChoiJ-S. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. Int J Pharm. 2007;337(1–2):188–193. doi:10.1016/j.ijpharm.2007.01.00217267149
   PubMed Web of Science ®Google Scholar
• ShenL, WangJ, YiY, et al. Inhibitory effect of isavuconazole, ketoconazole and voriconazole on the pharmacokinetics of methadone in vivo and vitro. Drug Test Anal. 2018;11(4):595–600. doi:10.1002/dta.253430370647
   PubMed Web of Science ®Google Scholar
• LinQM, PangNH, LiYH, et al. Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019;310:108744. doi:10.1016/j.cbi.2019.10874431299239
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for industry: bioanalytical method validation; 2018 Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry. Accessed 414, 2020.
   Google Scholar
• EMEA. Committee for medicinal products for human use, guideline on bioanalytical method validation; 2011 Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf. Accessed 414, 2020.
   Google Scholar
• ZhouD, AnderssonTB, GrimmSW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 2011;39(4):703. doi:10.1124/dmd.110.03714321177984
   PubMed Web of Science ®Google Scholar
• EkinsS, RingBJ, GraceJ, Mcrobie-BelleDJ, WrightonSA. Present and future in vitro approaches for drug metabolism. J Pharmacol Toxicol Methods. 2000;44(1):313–324. doi:10.1016/S1056-8719(00)00110-611274898
   PubMed Web of Science ®Google Scholar
• GaoJ, RenH, FengZ, et al. Effects of multidose simvastatin co-administration on pharmacokinetic profile of apatinib in rats by UPLC-MS/MS1. Xenobiotica. 2020;1–21. doi:10.1080/00498254.2020.1740952
   Web of Science ®Google Scholar
• OrlandoR, PiccoliP, De MartinS, et al. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin Pharmacol Ther. 2004;75(1):80–88. doi:10.1016/j.clpt.2003.09.00714749694
   PubMed Web of Science ®Google Scholar
• PrueksaritanontT, MaB, YuN. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol. 2003;56(1):120–124. doi:10.1046/j.1365-2125.2003.01833.x12848784
   PubMed Web of Science ®Google Scholar
• DickeyEJ, BrownKA, de SolisCN, SOLISCN. Serum concentrations of lidocaine and its metabolites after prolonged infusion in healthy horses. Equine Vet J. 2010;40(4):348–352. doi:10.2746/042516408X284664
   Web of Science ®Google Scholar